GraMedica, Lovell expand federal access to HyProCure

By AI, Created 9:47 AM UTC, May 20, 2026, /AGP/ – GraMedica and Lovell Government Services have partnered to make HyProCure available to VA, Defense, and Indian Health Service buyers through federal contract channels. The deal aims to widen access for veterans, active service members, and tribal healthcare systems using an SDVOSB-backed procurement path.

Why it matters: - The partnership gives federal healthcare systems a new path to buy HyProCure, a device GraMedica says is the only FDA-cleared Type II extra-osseous talotarsal stabilization device. - The agreement is aimed at veterans, active-duty service members, and tribal patients who receive care through the VA, Military Health System, and Indian Health Service. - Lovell’s SDVOSB status is meant to help federal agencies meet small-business procurement goals while expanding access to a specialty implant.

What happened: - Lovell Government Services and GraMedica announced a partnership on May 7, 2026. - The companies will serve federal healthcare systems, including the Veterans Health Administration, Military Health System, and Indian Health Service. - Lovell will act as GraMedica’s Service-Disabled Veteran-Owned Small Business vendor of record. - HyProCure is now available to federal buyers through the VA Federal Supply Schedule, Defense Logistics Agency Electronic Catalog, and GSA Advantage.

The details: - GraMedica says HyProCure treats talotarsal instability, a structural cause of adult flatfoot, hyperpronation, and related lower-extremity problems. - The procedure uses a 1.5 cm sinus tarsi incision under local anesthesia and takes about 20 minutes. - The implant is designed to stabilize hindfoot displacement while preserving joint motion. - Patients are typically full weight-bearing within 3 to 4 days without casting. - GraMedica says the implant is reversible if clinically indicated. - More than 100,000 HyProCure implants have been placed worldwide. - More than 100 independent peer-reviewed publications across more than 12 countries support the product’s clinical evidence base. - A U.S. cohort study cited by the company reported a 95.5% implant retention rate, a mean post-operative pain score of 1.0 on a 10-point scale, and 94% of patients saying they would recommend the procedure. - GraMedica says HyProCure is made in the USA and TAA compliant. - The company was founded in 2004 and is headquartered in Rochester, Michigan. - GraMedica is a wholly owned subsidiary of ADDvise Group AB, part of Amplex AB. - Lovell Government Services has operated as an SDVOSB vendor since 2013 and works with medical and pharmaceutical manufacturers in the federal market. - Lovell is a three-time Inc. 5000 honoree.

Between the lines: - The partnership pairs a device manufacturer with a federal contracting specialist, which can matter as much as product approval in government healthcare purchasing. - GraMedica is signaling that federal market access is a strategic priority for its parent company’s healthcare business. - Chris Lovell said the deal should help turn FDA clearance into actual access for veterans, active service members, and their dependents. - Foot and ankle pathology is a high-volume issue in the federal healthcare system, and a VA report cited in the release said ankle motion limitation was the eighth most prevalent service-connected disability among newly compensated veterans in FY2024. - The release also cites a VA medical center study linking chronic plantar fasciitis patients with radiographic hyperpronation.

What’s next: - Federal buyers can now pursue HyProCure through the listed contracting vehicles rather than a direct specialty procurement path. - The companies are betting the arrangement will speed adoption across VA, DoD, and IHS facilities. - More federal use could follow if agencies view the device as a fit for their orthopedic and podiatry needs.

The bottom line: - GraMedica and Lovell are trying to turn a specialized FDA-cleared implant into a practical purchasing option for federal health systems.